HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced promising topline data from its Phase 2b ANTHEM-UC clinical trial evaluating icotrokinra (JNJ-2113) as a treatment for moderately to severely active ...
Johnson & Johnson reported smaller compensation packages for three top executives and disclosed pay for new medical device ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback